The MarketWatch News Department was not involved in the creation of this content. Submission begins 45 day approval period, paving way for start up of first reactor at INL's DOME facility next year.

The indication was restricted to only patients with DMD who are 4 years of age and older with a confirmed mutation in the DMD gene; the indication for non-ambulatory patients with DMD was removed.

Zymeworks surges on positive Phase 3 Ziihera data in HER2-positive cancer. Discover key catalysts and what’s next for ZYME ...

Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration ...

A car’s build sheet is based on the car’s unique vehicle identification number (VIN). It lists both standard and optional ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrol ...

The agency is cautioning patients about the risk of serious, possibly fatal, liver injuries and has limited the gene therapy's use to ambulatory patients.

Money market funds in Kenya have quietly transformed from niche capital market products into the most powerful savings engines in the country ...

Presented detailed efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Me ...

Families file wrongful death lawsuit against Camp Mystic after six young girls died in Guadalupe River flooding, alleging ...

TWAICE says California’s Senate Bill 283 will shift developers’ focus from hardware redesign to proactive documentation and data-driven safety compliance.